Newswire (Published: Monday, September 9, 2019, Received: Monday, September 9, 2019, 6:11:10 PM CDT)

Word Count: 398

2019 SEP 09 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting out of Chapel Hill, United States, by NewsRx editors, research stated, “Men diagnosed with localized prostate cancer have many curative treatment options including several different radiotherapeutic approaches. Proton radiation is one such radiation treatment modality and, due to its unique physical properties, offers the appealing potential of reduced side effects without sacrificing cancer control.”

Funders for this research include Massachusetts General Hospital, Prostate Cancer Foundation.

Our news journalists obtained a quote from the research from the University of North Carolina, “In this review, we examine the intriguing dosimetric rationale and theoretical benefit of proton radiation for prostate cancer and highlight the results of preclinical modeling studies. We then discuss the current state of the clinical evidence for proton efficacy and toxicity, derived from both large claim-based datasets and prospective patient-reported data. The result is that the data are mixed, and clinical equipoise persists in this area. We place these studies into context by summarizing the economics of proton therapy and the changing practice patterns of prostate proton irradiation.”

According to the news editors, the research concluded: “Finally, we await the results of a large prospective randomized clinical trial currently accruing and also a large prospective pragmatic comparative study which will provide more rigorous evidence regarding the clinical and comparative effectiveness of proton therapy for prostate cancer.”

For more information on this research see: Proton Therapy for Prostate Cancer: a Review of the Rationale, Evidence, and Current State. Urologic Oncology Seminars and Original Investigations, 2019;37(9):628-636. Urologic Oncology Seminars and Original Investigations can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA.

Our news journalists report that additional information may be obtained by contacting T.J. Royce, University of North Carolina, Dept. of Radiation and Oncology, School of Medicine, Chapel Hill, NC 27515, United States.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.urolonc.2018.11.012. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

The Massachusetts General Hospital
The University of North Carolina

Places

North America
United States
Americas
North Carolina
New York
Chapel Hill
New York City

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Healthcare Management
            Healthcare Economics
      Health Sciences
            Medical Research
      Treatments and Therapies